Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sumitomo to Beef Up Promotional Efforts for Lullan
June 21, 2004
- Renal Function Improved by Concomitant ACEI, ARB:JSN Meeting
June 21, 2004
- Teijin Pharma Looking for M&A Opportunity: Mr Ohyagi
June 21, 2004
- Diabetics Taking Lipitor Show Major Decreases in Heart Attacks, Strokes: ADA Meeting
June 21, 2004
- WEBSITE NEWS
June 21, 2004
- Genes to Predict Paclitaxel Effects Discoverd
June 21, 2004
- Wholesalers May Tie Up with Non-wholesalers: Mr Kimura of CR&C
June 21, 2004
- Uracil + Tegafur Improve Postoperative Survival in Rectal Cancer Patients: ASCO
June 21, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 14, 2004
- Research on Iressa Progressing at the Gene Level
June 14, 2004
- Bezafibrate Inhibits Onset of Diabetes Mellitus: Kissei
June 14, 2004
- 26 Listed Makers Report 0.6% Decline in Consolidated Sales: Survey
June 14, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
June 14, 2004
- WORLD NEWS IN BRIEF
June 14, 2004
- OTC NEWS IN BRIEF
June 14, 2004
- Listed Makers Report Decline in Sales, Strong Increase in Net Profits on Non-consolidated Basis
June 14, 2004
- Annual Business Results
June 14, 2004
- Wakamoto: Ethical Drug Sales Fall 3% to \6.5 Bil.
June 14, 2004
- MEDICAL DEVICE NEWS IN BRIEF
June 14, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
June 14, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…